Ci spiace, ma questo articolo è disponibile soltanto in Inglese Americano.
The year 2024 marks a crucial milestone for Mistral, with the launch of major clinical trials in collaboration with centers of excellence throughout Italy.
Mistral is a certified medical device (CEE 93/42) that captures volatile organic compounds (VOCs) in human breath with a simple exhalation. Thanks to advanced analysis performed by the Mistral Lab, these compounds are identified to trace each individual’s metabolic fingerprint, providing valuable insights into their physiopathological condition.
In 2024, Mistral technology has been integrated into several clinical trials aimed at investigating the role of VOCs in the early screening of various diseases.
As of October 2024, new trials have been launched at the following hospitals and medical centers:
- Miulli Hospital (Acquaviva): study on prostate cancer
- IFO – Istituti Fisioterapici Ospedalieri (Rome): trial on head and neck cancers
- LUCEA Multimedica Center (Monopoli): clinical study on colorectalcancer
- Rete Salute Calabrese Institute: clinical trial on lungcancer
The results from 2024 represent a decisive step toward the wider adoption of Mistral technologies in medical research. Thanks to strong collaboration with leading healthcare institutions, 2025 is set to be a key year to consolidate the progress made and to demonstrate the full potential of breath analysis in the early screening of various diseases.
